Coronavirus: Inside the first-of-its-kind genetic vaccine trial

Researchers at NYU have started clinical trials on a new vaccine developed by Pfizer and a German partner. The vaccine attempts to reprogram the genetic code of the coronavirus rather than manipulate the live virus so that the body will produce antibodies to fight off COVID-19.May 6, 2020